Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 20 of 88 · 4178 articles
Metabolic interactions between epithelial and immune cells may help explain persistent inflammation and barrier problems in IBD and point to new therapeutic targets that could complement current immune-targeting drugs.
The review links changes in the microbiome and microbial polyamine production to immune cell imbalance that can drive both oral inflammation and IBD. Understanding this pathway could point to new research directions and...
ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.
Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.
Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...
The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...
A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.
This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...
AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...
Colon-targeted prednisolone devices could lower upper-GI exposure to steroids and provide sustained local therapy, which may be relevant for IBD treatment strategies if later validated in vivo and in clinical trials.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Canadian Medical Association Journal.
Abnormal liver tests are common in children with IBD and can come from many causes, including the disease itself or the medicines used to treat it. A practical approach helps avoid stopping effective IBD therapy...
A rare but serious neurological complication (Guillain–Barré syndrome) occurred alongside a severe UC flare after abrupt vedolizumab withdrawal, so people with UC should be aware that sudden neurologic weakness needs...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
Fatigue markedly affects quality of life for people with Crohn’s and often remains after inflammation is controlled. Recognizing multiple drivers — psychological distress and immune/hematologic signals — could change how...
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...
Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...
Finding genetic variants that correlate with country-level IBD burden could help researchers study why IBD rates differ geographically and point to biological pathways relevant to disease risk and outcomes.
This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...
This project targets epithelial repair — a mechanism not directly addressed by most current IBD drugs — and reports early human safety/tolerability data, so it could lead to a new oral therapy for inducing and...
Researchers are studying how gut bacteria evade therapeutic phages, which could affect development of phage-based treatments for drug-resistant infections and potentially influence understanding of bacteria linked to IBD...
Malnutrition and impaired growth are common at diagnosis in paediatric IBD—especially Crohn’s disease—and identifying these issues early can guide nutrition and treatment planning. Most underweight children in this study...
This study maps a shared transcriptional programme linking inflamed IBD tissue to colorectal cancer pathways, highlighting potential biomarker and prevention targets relevant to the inflammation-to-cancer transition.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Alimentary Pharmacology &...
Cure8 found this source from jo24.net, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Symptoms and flares. Open the original article for the full...
Cure8 found this source from health.usnews.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Symptoms and flares. Open the original article for the full...
Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.
The study shows pouchitis is a frequent postoperative problem in children after RPC‑IPAA and that many will still require advanced IBD medications, so surgery may not end medical therapy needs.
Atypical HUS is a rare, potentially life-threatening thrombotic microangiopathy that can be triggered by systemic inflammation such as IBD. Early recognition and complement testing can change management and may lead to...
Tools that predict which microbial or tumor peptides engage patient T cells could help researchers find antigens that trigger or drive autoimmune conditions (like some IBD cases) or that serve as targets for...
This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
Consistent, accurate endoscopic scoring matters for treatment decisions and trial outcomes in pediatric IBD. If focused training meaningfully improves scoring—especially for SES‑CD—it could reduce variability in clinical...
If confirmed, genetic evidence that higher omega-3 levels or a lower omega-6/omega-3 ratio relate to lower Crohn’s disease risk could point to biological pathways worth studying and might guide research into prevention...
IBD patients have higher risk of colitis-associated colorectal cancer; this study suggests dietary choline might protect the intestinal barrier and reduce inflammation-driven tumor risk via a nutrient–transporter–Notch1...
People with IBD in remission commonly continue to have IBS-like symptoms; this review summarizes randomized trial evidence for symptom-directed treatments and finds no definitive best option.
Researchers are exploring ways to durably modulate macrophages in ulcerative colitis because persistent pro-inflammatory macrophages sustain tissue inflammation and impair healing.
Researchers are exploring natural compounds that might modulate immune pathways implicated in IBD. This study highlights ergothioneine as a bioactive mushroom compound that reduces pro-inflammatory signals in immune...
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...
Cure8 could only read part of this source from fox2detroit.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness.
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the full...
If confirmed, starting effective biologic therapy at diagnosis could lower the chance of surgery and complications over several years for people with moderate-to-severe Crohn’s disease.
The release reports many active and planned clinical trials for Crohn’s disease that could lead to new treatment options in coming years. It names specific late-stage and combination studies relevant to patients with...
Reported IBD rates in Brazil increased markedly between 2012 and 2025, which could mean more people will need diagnosis, specialist care, and medications. Rising numbers also matter for public-health planning and...
